GLMD Galmed Pharmaceuticals Ltd. Stock Quote

GLMD [NASD]

Index	-	P/E	-	EPS (ttm)	-1.44	Insider Own	14.14%	Shs Outstand	23.37M	Perf Week	-4.60%
Market Cap	63.00M	Forward P/E	-	EPS next Y	-1.40	Insider Trans	0.00%	Shs Float	21.57M	Perf Month	-18.09%
Income	-31.60M	PEG	-	EPS next Q	-0.38	Inst Own	23.80%	Short Float	3.01%	Perf Quarter	-23.62%
Sales	-	P/S	-	EPS this Y	-39.50%	Inst Trans	0.18%	Short Ratio	2.35	Perf Half Y	-32.70%
Book/sh	2.27	P/B	1.10	EPS next Y	6.00%	ROA	-53.20%	Target Price	-	Perf Year	-48.87%
Cash/sh	2.32	P/C	1.07	EPS next 5Y	20.00%	ROE	-60.00%	52W Range	2.15 - 6.25	Perf YTD	-19.94%
Dividend	-	P/FCF	-	EPS past 5Y	-7.20%	ROI	-	52W High	-60.16%	Beta	2.18
Dividend %	-	Quick Ratio	8.40	Sales past 5Y	-	Gross Margin	-	52W Low	15.81%	ATR	0.14
Employees	18	Current Ratio	8.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.34	Volatility	5.02% 5.32%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-32.90%	Profit Margin	-	Rel Volume	0.23	Prev Close	2.51
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 05 BMO	Payout	-	Avg Volume	275.60K	Price	2.49
Recom	1.80	SMA20	-9.65%	SMA50	-13.95%	SMA200	-26.06%	Volume	62,411	Change	-0.80%

May-22-20

Downgrade

B. Riley FBR

Buy → Neutral

$11 → $8

Feb-04-20

Initiated

Craig Hallum

Buy

$18

Jan-30-20

Resumed

Cantor Fitzgerald

Overweight

$9 → $14

Dec-02-19

Initiated

Canaccord Genuity

Buy

Dec-12-18

Initiated

B. Riley FBR

Buy

$28

Aug-02-18

Reiterated

Maxim Group

Buy

$30 → $27

Jul-13-18

Initiated

Stifel

Buy

$35

Jul-12-18

Initiated

Cantor Fitzgerald

Overweight

$59

Jun-12-18

Reiterated

H.C. Wainwright

Buy

$24 → $43

Mar-15-18

Upgrade

Maxim Group

Hold → Buy

$14

Feb-14-18

Downgrade

Maxim Group

Buy → Hold

Feb-12-18

Reiterated

H.C. Wainwright

Buy

$18 → $24

Nov-15-17

Initiated

ROTH Capital

Buy

$32

Aug-08-17

Reiterated

H.C. Wainwright

Buy

$12 → $18

Jul-31-17

Reiterated

Maxim Group

Buy

$9 → $14

Aug-01-16

Reiterated

Maxim Group

Buy

$24 → $9

Jul-06-16

Resumed

ROTH Capital

Buy

Mar-28-16

Resumed

H.C. Wainwright

Buy

$22

Jun-23-15

Initiated

H.C. Wainwright

Buy

$21

May-06-15

Initiated

Sun Trust Rbsn Humphrey

Buy

$20

Jul-29-21 08:30AM	Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5 PR Newswire
Jun-04-21 06:57AM	Why Is Penny Stock Galmed Pharma A Strong Buy With Triple-Digit Upside? TipRanks +24.09%
May-13-21 07:50AM	Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results PR Newswire -8.20%
06:30AM	Galmed Pharmaceuticals Ltd. to Host Earnings Call ACCESSWIRE
May-06-21 08:30AM	Galmed Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Business Update on Thursday May 13 PR Newswire -14.93%
May-03-21 08:30AM	Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global Phase 3 ARMOR Registrational Study PR Newswire
Mar-19-21 07:23AM	Galmed Dips 2% On Larger-Than-Expected Quarterly Loss SmarterAnalyst +14.62%
Mar-18-21 07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results PR Newswire
06:30AM	Galmed Pharmaceuticals Ltd. to Host Earnings Call ACCESSWIRE
Mar-16-21 08:00AM	Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER PR Newswire
Mar-11-21 08:30AM	Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18 PR Newswire
Feb-16-21 09:29AM	Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares PR Newswire -5.57%
06:48AM	Galmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares PR Newswire
Feb-11-21 11:16AM	These 2 Penny Stocks Could Rack up Triple-Digit Gains, Say Analysts TipRanks +22.45%
Feb-04-21 01:30AM	Are Institutions Heavily Invested In Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) Shares? Simply Wall St.
Jan-26-21 08:00AM	Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism of Action PR Newswire
Jan-19-21 08:00AM	Galmed Hosting KOL Symposium and Pipeline Update PR Newswire
Dec-17-20 07:00AM	Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021 PR Newswire -12.16%
Dec-04-20 09:08AM	Is Galmed Pharmaceuticals Ltd (GLMD) A Good Stock To Buy? Insider Monkey -5.41%
Nov-12-20 07:00AM	Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results PR Newswire -5.65%
06:45AM	Galmed Pharmaceuticals Ltd. to Host Earnings Call ACCESSWIRE
Nov-10-20 08:40AM	The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga
Nov-09-20 08:00AM	Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol PR Newswire -8.93%
Nov-05-20 08:30AM	Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12 PR Newswire
Oct-20-20 08:31AM	We're Hopeful That Galmed Pharmaceuticals (NASDAQ:GLMD) Will Use Its Cash Wisely Simply Wall St.
Sep-10-20 08:49AM	Galmed and Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist) PR Newswire
Aug-06-20 07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results PR Newswire -7.24%
06:50AM	Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program PR Newswire
Jul-30-20 08:30AM	Galmed Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on Thursday August 6 PR Newswire +7.27%
Jul-22-20 10:34AM	How Is Galmed Pharmaceuticals' (NASDAQ:GLMD) CEO Paid Relative To Peers? Simply Wall St.
Jul-14-20 05:31PM	3 Healthcare Stocks Under $5 With Triple-Digit Upside Potential TipRanks +5.36%
Jul-06-20 07:55AM	Here is What Hedge Funds Think About Galmed Pharmaceuticals Ltd (GLMD) Insider Monkey
Jun-26-20 06:42AM	Edited Transcript of GLMD earnings conference call or presentation 14-May-20 12:30pm GMT Thomson Reuters StreetEvents
Jun-10-20 08:34AM	How Galmed (GLMD) Stock Stands Out in a Strong Industry Zacks
May-14-20 05:31PM	After Drug Failure, Genfit's Cupboard Is Nearly Bare GuruFocus.com
07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results PR Newswire
May-07-20 08:30AM	Galmed Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on Thursday May 14 PR Newswire
May-02-20 09:36AM	Such Is Life: How Galmed Pharmaceuticals (NASDAQ:GLMD) Shareholders Saw Their Shares Drop 54% Simply Wall St.
Mar-26-20 09:40PM	Edited Transcript of GLMD earnings conference call or presentation 12-Mar-20 12:30pm GMT Thomson Reuters StreetEvents
Mar-12-20 07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2019 Financial Results PR Newswire -19.48%
Mar-05-20 08:30AM	Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12 PR Newswire
Feb-28-20 09:30AM	BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher Zacks
Feb-05-20 04:11PM	13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market Benzinga
Jan-03-20 08:25AM	Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Overpaid Relative To Its Peers? Simply Wall St.
Dec-14-19 07:21PM	Do Hedge Funds Love Galmed Pharmaceuticals Ltd (GLMD)? Insider Monkey
Dec-04-19 09:26AM	Top Ranked Momentum Stocks to Buy for December 4th Zacks +18.42%
Nov-29-19 08:41AM	NASH Scorecard Year to Date: The Winners and the Losers Zacks
Nov-08-19 10:57PM	Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-06-19 07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results PR Newswire -10.11%
Nov-04-19 09:10AM	Such Is Life: How Galmed Pharmaceuticals (NASDAQ:GLMD) Shareholders Saw Their Shares Drop 60% Simply Wall St. +5.26%
Oct-31-19 08:30AM	Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019 PR Newswire +13.11%
Oct-30-19 08:30AM	Galmed Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on Wednesday, November 6 PR Newswire
Sep-26-19 08:00AM	Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and Fibrosis PR Newswire
Sep-19-19 01:05PM	Should You Buy Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) For This Reason? Simply Wall St. +7.87%
Aug-12-19 04:33AM	Edited Transcript of GLMD earnings conference call or presentation 5-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-05-19 07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results PR Newswire -13.76%
Jul-29-19 08:30AM	Galmed Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on Monday, August 5 PR Newswire
Jul-24-19 01:17PM	Could The Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Ownership Structure Tell Us Something Useful? Simply Wall St. +7.43%
May-23-19 12:37PM	Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Being Overpaid? Simply Wall St.
May-07-19 08:25AM	Galmed Pharmaceuticals (GLMD) Reports Q1 Loss, Misses Revenue Estimates Zacks -5.45%
07:21AM	Galmed Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results PR Newswire
Apr-30-19 08:30AM	Galmed Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 7 PR Newswire
Apr-09-19 07:30AM	Galmed Pharmaceuticals Announces Successful Completion of End of Phase 2 Meeting With FDA and Plan for Start of Phase 3 PR Newswire
Mar-13-19 08:25AM	Galmed Pharmaceuticals (GLMD) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:00AM	Galmed Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update PR Newswire
Mar-12-19 10:02AM	Update: Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Gained 95% In The Last Three Years Simply Wall St.
08:00AM	Galmed Reports Positive Results From Pharmacokinetic Split Dose Study of Aramchol PR Newswire
Mar-06-19 08:30AM	Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2018 Financial Results and Provide Business Update on Wednesday, March 13 PR Newswire -5.04%
Dec-28-18 04:52PM	Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018 Zacks
Dec-12-18 02:26PM	What does Galmed Pharmaceuticals Ltd.s (NASDAQ:GLMD) Balance Sheet Tell Us About Its Future? Simply Wall St. +18.56%
Dec-11-18 09:22AM	Novan Announces Top-Line Data From Mid-Stage Molluscum Study Zacks -5.38%
Nov-20-18 08:45AM	Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher Zacks -5.48%
Nov-14-18 07:50AM	Recent Analysis Shows COUPA SOFTWARE, Galmed Pharmaceuticals, Sunworks, Murphy, Diversicare Healthcare Services, and Pro-Dex Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-13-18 11:30AM	Phase 2 Data for Galmed Pharmaceutical's Aramchol in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018 PR Newswire -7.01%
04:02AM	Galmed Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-05-18 08:45AM	Galmed Pharmaceuticals (GLMD) Reports Q3 Loss, Tops Revenue Estimates Zacks +5.37%
07:39AM	Galmed Pharmaceuticals: 3Q Earnings Snapshot Associated Press
07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2018 Financial Results PR Newswire
Oct-31-18 03:38PM	Nantahala Capital Managements Returns, AUM, and Holdings Insider Monkey
Oct-29-18 08:30AM	Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5 PR Newswire
Oct-12-18 03:21PM	Who Really Owns Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)? Simply Wall St.
Oct-02-18 08:39AM	Galmed Pharmaceuticals Announces a Late-Breaking Abstract on Aramchol to be Presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® PR Newswire
Sep-27-18 08:00AM	Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference PR Newswire
Aug-02-18 05:40PM	Medical-Drugs Stock Outlook: No Respite from Near-Term Pain Zacks
10:55AM	Galmed Pharmaceuticals (GLMD) Reports Q2 Loss Zacks
09:51AM	Galmed Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results PR Newswire
Jul-26-18 08:30AM	Galmed Pharmaceuticals to Report Second Quarter 2018 Financial Results and Provide Business Update on Thursday, August 2 PR Newswire
Jul-20-18 11:42AM	What's in Store for Universal Health's (UHS) Q2 Earnings? Zacks
11:26AM	What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings? Zacks
Jul-13-18 07:02PM	Here's Why Galmed Pharmaceuticals Ltd. Was Up 19% Today and 33% for the Week Motley Fool
10:49AM	Galmed Notches Second Bullish Rating On Aramchol Opportunity Benzinga
08:00AM	Today's Research Reports on Stocks to Watch: Galmed Pharmaceuticals and Zogenix ACCESSWIRE
Jul-12-18 12:11PM	Cantor Fitzgerald Makes An Uber-Bullish Call On Galmed Pharmaceuticals Benzinga
08:00AM	Today's Research Reports on Trending Tickers: Galmed Pharmaceuticals and Akcea Therapeutics ACCESSWIRE
Jun-26-18 07:06AM	This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It Motley Fool
Jun-25-18 07:30AM	Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock ACCESSWIRE
Jun-20-18 08:36AM	Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading Benzinga
Jun-19-18 09:37PM	Galmed Pharmaceuticals Ltd. Announces Pricing of Public Offering of Ordinary Shares PR Newswire

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience